Joachim Von Pawel

Joachim Von Pawel

UNVERIFIED PROFILE

Are you Joachim Von Pawel?   Register this Author

Register author
Joachim Von Pawel

Joachim Von Pawel

Publications by authors named "Joachim Von Pawel"

Are you Joachim Von Pawel?   Register this Author

88Publications

2954Reads

19Profile Views

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2017 Oct 30;35(30):3449-3457. Epub 2017 Aug 30.

Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Aleksandra Szczesna, Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University, Seoul; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju-si, Republic of Korea; Claus-Peter Schneider, Zentralklinik Bad Berka, Bad Berka; Joachim Von Pawel, Asklepius Fachkliniken, Gauting; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; Pablo Fernando Gonzalez Mella, Centro de Investigaciones Clinicas, Universidad de Valparaíso and Fundación Arturo López Pérez, Santiago, Chile; Fabrice Barlesi, Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France; Baohui Han, Shanghai Chest Hospital Affiliated to Shanghai JiaoTong University, Shanghai; Li Zhang, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China; Doina Elena Ganea, Spitalul Judetean De Urgenta Suceava, Sfântul loan cel Nou, Suceava, Romania; Vladimir Vladimirov, State Healthcare Institute, Pyatigorsk Oncology Dispensary, Pyatigorsk; Natalia Fadeeva, Chelyabinsk Regional Oncology Dispensary, Chelyabinsk, Russian Federation; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Tomohide Tamura, St Luke's International Hospital, Tokyo, Japan; Pieter E. Postmus, University of Liverpool, Liverpool, United Kingdom; Kenneth O'Byrne, Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Queensland, Australia; and Justin Kopit, Mingshun Li, and Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.7629
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.7629DOI Listing
October 2017

Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.

Target Oncol 2017 08;12(4):475-485

Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), 22927, Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-017-0517-2DOI Listing
August 2017

Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.

Lung Cancer 2017 03 9;105:1-6. Epub 2017 Jan 9.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayamashi, Osaka 589-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.12.018DOI Listing
March 2017

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial.

Onco Targets Ther 2017 21;10:1081-1089. Epub 2017 Feb 21.

University Hospital Munich and Thoracic Oncology Centre Munich, Member of the German Center for Lung Research, Comprehensive Pneumology Center Munich (DZL CPC-M), Munich.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S122106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328303PMC
February 2017

Editorial.

Int J Clin Pharmacol Ther 2015 Dec;53(12):1037

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5414/cpces14ediDOI Listing
December 2015

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2015 Aug 13;33(24):2667-74. Epub 2015 Jul 13.

Giorgio Scagliotti and Silvia Novello, University of Turin, Orbassano, Torino; Adolfo Favaretto, Istituto Oncologico Veneto, Padova; Armando Santoro, Istituto Clinico Humanitas, Milan, Italy; Joachim von Pawel, Asklepios-Fachkliniken München-Gauting, Munich, Germany; Rodryg Ramlau, Poznań University of Medical Sciences, Poznań, Poland; Fabrice Barlesi, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Wallace Akerley, Huntsman Cancer Institute, Salt Lake City, UT; Sergey Orlov, St Petersburg State Medical University, St Petersburg, Russian Federation; David Spigel, Clinical Locations, Nashville, TN; Vera Hirsh, McGill University Health Centre, Montreal, Quebec; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Lecia V. Sequist, Massachusetts General Hospital, Boston; Jeffrey S. Ross, Foundation Medicine, Cambridge; Brian Schwartz, ArQule, Woburn, MA; Alan Sandler, Genentech, San Francisco, CA; and Qiang Wang, Reinhard von Roemeling, and Dale Shuster, Daiichi Sankyo, Edison, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.7317DOI Listing
August 2015

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

J Clin Oncol 2014 Dec 10;32(35):4012-9. Epub 2014 Nov 10.

Joachim von Pawel, Asklepios Fachkliniken München-Gauting, Gauting; Jörg Mezger, St Vincentius-Kliniken Karlsruhe, Karlsruhe; Martin Steins, Thoraxklinik am Universitätsklinikum, Heidelberg; Wolfgang Schütte, Krankenhaus Martha-Maria Halle-Dölau, Halle; Martin Reck, Krankenhaus Großhansdorf, Großhansdorf, Germany; Robert Jotte, Rocky Mountain Cancer Center, Denver, CO, and US Oncology, Houston, TX; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Mary E.R. O'Brien, Royal Marsden National Health Service (NHS) Foundation Trust, Surrey; Paul Lorigan, Christie NHS Foundation Trust, Manchester, United Kingdom; Mark A. Socinski, University of Pittsburgh Medical Center, Pittsburgh, PA; Léon Bosquée, Centre Hospitalier Universitaire Sart-Tilman, Liège; Kristiaan Nackaerts, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; Jeffrey Bubis, Cancer Specialists of North Florida, Jacksonville, FL; José M. Trigo, Hospital Universitario Virgen de la Victoria, Malaga; Manuel Domine, Fundación Jiménez Diaz, Universidad Autónoma de Madrid, Madrid, Spain; Philip Clingan, Southern Medical Day Care Centre, Wollongong, New South Wales, Australia; Frances A. Shepherd, University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Shaoyi Li and Markus F. Renschler, Celgene, Summit, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.5392DOI Listing
December 2014

DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.

Lung Cancer 2014 Aug 21;85(2):224-9. Epub 2014 May 21.

IRCCS AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.05.013DOI Listing
August 2014

Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.

J Thorac Oncol 2014 Jan;9(1):126-31

*Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; †IBIS (Virgen del Rocio Hospital, Seville University & CSIC), Seville, Spain; ‡Cancer Care Center of Frederick, Frederick, Maryland; §Asklepios Klinik Harburg, Hamburg, Germany; ‖Royal Victoria Hospital, Division of Medical Oncology, Montreal, Canada; ¶Eli Lilly and Company, Indianapolis, Indiana; and #Asklepios Klinikum Gauting, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000037DOI Listing
January 2014

Annual meeting of CESAR in Tuebingen, Germany June 27-29, 2013.

Int J Clin Pharmacol Ther 2014 Jan;52(1):73

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5414/cpp52073DOI Listing
January 2014

An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.

J Thorac Oncol 2013 Dec;8(12):1529-37

*Department of Clinical and Biological Sciences, University of Turin, Orbassano, Torino, Italy; †Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; ‡Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France; §Asklepios Clinic, Asklepios Fachkliniken München-Gauting, Gauting, Germany; ‖Department of Oncology, Herlev Hospital, Onkologisk afdeling, Herlev, Denmark; ¶Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany; #Department of Respiratory Medicine, Centre Hospitalier Universitaire de Liege, Liege, Belgium; **Department of Respiratory Medicine, Hopital Saint-Antoine, Paris Cedex, France; ††Department of Medical Oncology, Hospital de Mataro, Mataro, Spain; and ‡‡Oncology Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina; Collegeville, Philadelphia, Pennsylvania; and Uxbridge, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000005DOI Listing
December 2013

The emerging role of MET/HGF inhibitors in oncology.

Cancer Treat Rev 2013 Nov 28;39(7):793-801. Epub 2013 Feb 28.

Department of Oncology, University of Turin, San Luigi Hospital, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372130003
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2013.02.001DOI Listing
November 2013

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.

Lung Cancer 2012 Oct 9;78(1):1-7. Epub 2012 Aug 9.

Hematology/Oncology Division, Oregon Health Sciences University, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2012.07.004DOI Listing
October 2012

Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.

Oncol Rep 2012 Aug 18;28(2):721-7. Epub 2012 May 18.

Division of Oncology, Tel Aviv Medical Center, Tel-Aviv 64239, Israel.

View Article

Download full-text PDF

Source
https://www.spandidos-publications.com/10.3892/or.2012.1824
Publisher Site
http://dx.doi.org/10.3892/or.2012.1824DOI Listing
August 2012

Long-term stability of circulating nucleosomes in serum.

Anticancer Res 2010 May;30(5):1613-5

Institute of Clinical Chemistry, University Hospital Munich-Grosshadern, Munich, Germany.

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/content/30/5/1613.full.pdf
Web Search
May 2010

Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.

Anticancer Res 2010 May;30(5):1855-62

Institute of Clinical Chemistry, University Hospital Munich-Grosshadern, Munich, Germany.

View Article

Download full-text PDF

Source
May 2010

Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.

Respir Med 2010 Jan 8;104(1):142-8. Epub 2009 Oct 8.

Department of Pneumology and Thoracic Surgery, Hospital Grosshansdorf, Woehrendamm 80, D-22927 Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2009.07.019DOI Listing
January 2010

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

Lung Cancer 2009 Aug 5;65(2):192-7. Epub 2009 May 5.

Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, The University of Auckland, 85 Park Rd, Grafton, Private Bag 92019, Auckland 1142, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2009.03.027DOI Listing
August 2009

Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports.

Onkologie 2008 Mar 20;31(3):123-6. Epub 2008 Feb 20.

Klinik fur Pneumologie, Asklepios-Fachkliniken Munchen-Gauting, Gauting, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000113928DOI Listing
March 2008

[Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV].

Onkologie 2006 Sep 6;29 Suppl 2:15-9. Epub 2006 Sep 6.

Klinik für Pneumologie, Ruppiner Klinikum GmbH, Neuruppin, Deutschland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000094950DOI Listing
September 2006

Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments.

Ann N Y Acad Sci 2006 Sep;1075:244-57

Institute of Clinical Chemistry, University Hospital of Munich-Grosshadern, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1368.033DOI Listing
September 2006

Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.

Lung Cancer 2006 Aug 19;53(2):231-9. Epub 2006 Jun 19.

University of Pittsburgh School of Medicine, Lung and Thoracic Malignancies Program, University of Pittsburgh Cancer Institute, Cancer Pavilion, Floor 5, 5150 Centre Avenue Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2006.05.003DOI Listing
August 2006

Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer.

Clin Cancer Res 2004 Sep;10(18 Pt 1):5981-7

Institute of Clinical Chemistry, University of Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-0625DOI Listing
September 2004

Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.

Bull Cancer 2004 May 1;91(5):E70-6. Epub 2004 May 1.

Asklepios Fachkliniken, Robert-Koch-Allee 2, 82131 Gauting, Germany.

View Article

Download full-text PDF

Source
May 2004

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

J Clin Oncol 2003 Aug 1;21(16):3016-24. Epub 2003 Jul 1.

Division of Medical Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center Cancer Pavilion, 5150 Center Ave, Suite 570, Pittsburgh, PA 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.12.046DOI Listing
August 2003

The role of topotecan in treating small cell lung cancer: second-line treatment.

Lung Cancer 2003 Aug;41 Suppl 4:S3-8

Asklepios Fachklinik, Gauting bei Munchen, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(03)90519-8DOI Listing
August 2003

Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study.

Lung Cancer 2003 Jan;39(1):63-9

Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, D-22927 Grosshansdrof, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(02)00383-5DOI Listing
January 2003